Expression of Matrix Metalloproteinases-9 and Stromelysin-3 in Peripheral Blood in Patients with Lung Cancer.
10.4046/trd.2002.52.2.107
- Author:
Seong Yong LIM
1
;
Won Jung KOH
;
Cheol Hong KIM
;
Young Mee AHN
;
Young Mee KWON
;
Kyeong Woo KANG
;
Ho Cheol KIM
;
Gee Young SUH
;
Man Pyo CHUNG
;
Si Young LIM
;
Ho Joong KIM
;
O Jung KWON
Author Information
1. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. hjkim@smc.samsung.co.kr
- Publication Type:Original Article
- Keywords:
Matrix metalloproteinases;
Bronchogenic carcinoma;
Reverse transcriptase plolymerase chain reaction
- MeSH:
Carcinoma, Bronchogenic;
Diagnosis;
Enzyme-Linked Immunosorbent Assay;
Hand;
Humans;
Lung Neoplasms*;
Lung*;
Matrix Metalloproteinases;
Neoplasm Metastasis;
RNA, Messenger
- From:Tuberculosis and Respiratory Diseases
2002;52(2):107-116
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Matrix metalloproteinases(MMP) are essential enzymes for tumor invasion and metastasis. Among the MMP family, elevated MMP-9 and stromelysin-3(STR-3) expression have been reported to be poor prognostic factors in lung cancer patients. To evaluate the possibility of a molecular diagnosis of lung cancer using peripheral blood, the mRNA expression level of MMP-9 and STR-3 was measured using a reverse transcriptase-polymerase chain reaction(RT-PCR) in patients with lung cancer. METHODS: Ninety six patients(44 patients with lung cancer, 19 pulmonary infection, and 33 control) were included. To detect MMP-9 and STR-3 mRNA expression, RT-PCR was performed in peripheral blood mononuclear cells. ELISA was also used to measure the serum level of MMP-9. RESULTS: MMP-9 was expressed more frequently in patients with a pulmonary infection(18/19, 94.7%) compared to lung cancer patients(26/44, 59.1%) or the controls (23/33, 69.7%) (p=0.018). On the other hand, STR-3 expression was observed more frequently in patients with lung cancer(37/44, 84.1%) compared to the lung infection patients(8/19, 42.1%) or control(20/33, 60.6%) (p=0.003). Among the lung cancer patients, MMP-9 was expressed more frequently when a tumor invaded the lymph nodes(17/24, 70.8%) compared to when a tumor did not(3/13, 23.1%) (p=0.005). The MMP-9 and STR-3 expression levels had no relationship with age, sex, tumor size, distant metastasis, or tumor histology. The serum MMP-9 concentration was not higher in lung cancer patients compared to patients with a pulmonary infection or the control subjects. CONCLUSION: STR-3 may be used as a diagnostic marker in the peripheral blood of lung cancer patients using RT-PCR. Further studies to evaluate the clinical significance of elevated STR-3 expression in lung cancer patients is recommended.
